Target intelligence / Profile preview

OSER1 divergent transcript (OSER1-DT)

Target
OSER1-DT
Molecular classification
Long non-coding RNA (lncRNA), Other (non-coding RNA)
01

Overview

OSER1 divergent transcript (OSER1-DT, also known as OSER1-AS1 or OSER1 antisense RNA 1 (head to head)) is a long non-coding RNA gene located on chromosome 20q13.12. OSER1-DT is transcribed in the opposite orientation to the neighboring OSER1 gene. Functional studies indicate OSER1-DT acts as a tumor suppressor in certain cancers (including non-small cell lung cancer and hepatocellular carcinoma), likely through post-transcriptional regulation of target genes such as Smad2, Rab23, ELAVL1, and GPX4, partly by sponging microRNAs. OSER1-DT has demonstrated involvement in programmed cell death pathways (e.g., necroptosis, ferroptosis) and activation of specific immune pathways, but is not a protein, enzyme, or classical receptor, nor an established drug target.

Other names
OSER1-AS1OSER1 antisense RNA 1 (head to head)OSER1-DT
02

Mechanism of action

As a lncRNA, acts through modulation of other gene expression, often by microRNA sponging or RNA-RNA/protein interactions; not a direct pharmacological drug target.

03

Biological functions

Regulation of gene expression (acts via microRNA sponging or competitive binding)Modulation of cell death pathways (such as necroptosis and ferroptosis)Involvement in immune pathway activation (notably B-cell receptor pathway)
04

Disease associations

Cancer (tumor suppressor in non-small cell lung cancer, hepatocellular carcinoma)Possible role in immune-related diseases, e.g., periodontitisReported variant associations with Type 2 diabetes, blood cell traits, and monocyte count via GWAS
05

Safety considerations

Not applicable; no therapeutic agents targeting OSER1-DT are in use or under development, so no human safety data exists.
06

Biomarkers

No established biomarkers for therapeutic or diagnostic use; expression levels studied as potential biomarker in cancer and immune disease contexts

Beyond the preview

Go deeper on OSER1 divergent transcript (OSER1-DT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on OSER1 divergent transcript (OSER1-DT).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call